Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Management of Moderate to Severe Ulcerative Colitis: Treatment Approaches
  • CME
  • CE

Credits Available
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Released: November 13, 2020 Expiration: November 12, 2021
Start Activity
Provided by the American Gastroenterological Association, in collaboration with Clinical Care Options

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by an educational grant from
Pfizer, Inc.
Anita Afzali, MD, MPH, FACG
Millie D. Long, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recommendations from the latest UC management guidelines regarding next steps for patients with moderate to severely active UC
  • Consider the utility of the latest UC therapies that can better align with patients’ needs for a treatment that is convenient, effective, and safe

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Anita Afzali, MD, MPH, FACG

Associate Professor of Medicine
Medical Director, 
OSU Inflammatory Bowel Disease Center
Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease

Division of Gastroenterology, Hepatology and Nutrition
The Ohio State University Wexner Medical Center
Columbus, Ohio

Anita Afzali, MD, MPH, FACG, has disclosed that she has received consulting fees from AbbVie, Celgene/Bristol-Myers Squibb, Janssen, Pfizer, and Takeda; funds for research support from AbbVie, Celgene/Bristol-Myers Squibb, Janssen, Lilly, and Takeda; received fees for non-CME/CE services from AbbVie, Janssen, Pfizer, and Takeda; and received other financial material support from IBD Horizons.
Millie D. Long, MD, MPH

Associate Professor of Medicine
Director,
Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology 
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Millie D. Long, MD, MPH, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, Janssen, Pfizer, Prometheus, Salix, Target PharmaSolutions, UCB, and Valeant and funds for research support from Pfizer and Takeda.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.
David C. Howard

Editorial Contributor

David Howard, PharmD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Target Audience

The primary target audience for the activities includes gastroenterologists, nurses, nurse practitioners, and other healthcare providers who treat patients with ulcerative colitis.

Goal

The goal of this program to improve the competence and performance of clinician learners to select effective treatment for patients with moderate to severe ulcerative colitis (UC), including those with difficult-to-treat UC who have failed TNF inhibitor therapy.

Physician Continuing Medical Education

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The AGA Institute designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the American Gastroenterological Association. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 13, 2020, through November 12, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Summary
  • CME
  • CE

Loading...
Brief summary of key take-home points.
Anita Afzali, MD, MPH, FACG
Millie D. Long, MD, MPH
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Released: November 13, 2020 Expiration: November 12, 2021

This program is divided into several short segments which you can step through using the Video Chapters menu.

Related Content

Downloadable slides covering safety and efficacy data on new and emerging oral therapies for IBD, including S1PR modulators and JAK-STAT inhibitors.

Millie D. Long, MD, MPH Released: August 24, 2021

Interactive video from Dr. Millie Long and Clinical Care Options (CCO) on new and emerging oral IBD therapies

Millie D. Long, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: August 24, 2021 Expired: August 23, 2022

Expert commentary from Dr. Millie Long on the benefits of and barriers to patient participation in IBD clinical trials, from Clinical Care Options (CCO)

Millie D. Long, MD, MPH Released: August 17, 2021

Expert commentary from Dr. Millie Long on developing “activated” patients with IBD in your practice, from Clinical Care Options (CCO)

Millie D. Long, MD, MPH Released: July 13, 2021

Video Chapters


Provided by the American Gastroenterological Association, in collaboration with Clinical Care Options

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by an educational grant from
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue